AllDocs -> cancers

EVIDENCE-BASED SERIES #6-8 VERSION 2.2005 PRACTICE GUIDELINE – page 1 Evidence-based Series #6-8 Version 2.2005: Section 1 Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Clinical Practice Guideline K. Imrie, A. Stevens, R. Meyer, and the members of the Hematology Disease Site Group A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO) Developed by the Hematology Disease Site Group Original Report Date: February 17, 2005 Current Report Date: December 22, 2005 This evidence-based series replaces an evidence summary completed March 15, 1999 and published as: Imrie K, Esmail R, Buckstein R, Berinstein N, Meyer R, and the Hematology Disease Site Group. Use of rituximab in the treatment of lymphoma : an evidence summary. Curr Oncol. 1999;6(4):228-35. Questions Lymphoma 1. In patients with ...

Data Review of aplaviroc trials Judith Millard, PhD Group Director ID Medicines Development Center, GSK Page 2 Background information • Aplaviroc development stopped due to evidence of idiosyncratic hepatoxicity • 640 subjects dosed, >350 with multiple doses in phase IIb and III • Review of SAEs, AEs and HIV associated conditions – 3 reports found • Squamous cell carcinoma • Burkitt’s Lymphoma • “Possible Lymphoma ” • None reported as “drug related” Page 3 Squamous Cell Carcinoma • 41 y female randomized to COM+APL (600mg BID) – 01APR05: vaginal discharge with blood – 18APR05: enrolled into the APL trial – 28APR05: invasive epidernoid carcinoma of vagina diagnosed by biopsy – 17MAY05: hospitalized: ...

Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts Ulf Klein 1 , Annunziata Gloghini 2 , Gianluca Gaidano 3 , Amy Chadburn 4 , Ethel Cesarman 4 , Riccardo Dalla-Favera 1 , and Antonino Carbone 2 1 Institute for Cancer Genetics, and the Departments of Pathology and Genetics & Development, Columbia University, New York, NY10032, U.S.A. 2 Division of Pathology and Medical Oncology A, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy 3 Hematology Unit, Division of Internal Medicine, Department of Medical Sciences & IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy 4 Department of Pathology, ...

137 Colon and Rectum Summary Male Female Utah 1996-2000 US 1996-99 Utah 1996-2000 US 1996-99 Average annual age-adjusted incidence rates* 23.4 23.5 14.3 15.9 Rank among cancer incidence rates 6 5 7 6 Average annual number of new cases 163 27,580 117 23,690 Percent of all new cancer cases 5.0 % 4.3 % 4.1 % 3.8 % * Rates per 100,000 and standardized to the 2000 U.S. population Lifetime risk this of cancer (00-79 years) 1 in 44 1 in 44 1 in 68 1 in 62 Average annual age-adjusted mortality rates* 10.5 10.8 7.1 7.2 Rank among cancer mortality rates 4 5 5 6 Average annual number of deaths 68 12,047 58 11,115 Percent of all cancer deaths 5.7 % 4.3 % ...

Hodgkin Lymphoma Protocol applies to Hodgkin lymphoma involving any organ system except for the gastrointestinal tract. Protocol revision date: January 2005 No AJCC/UICC staging system Procedures • Cytology (No Accompanying Checklist) • Biopsy • Staging Procedure Authors Jonathan Said, MD Department of Pathology, UCLA School of Medicine, Los Angeles, California Carolyn Compton, MD, PhD Department of Pathology, McGill University, Montreal, Quebec, Canada For the Members of the Cancer Committee, College of American Pathologists Previous contributors: Judith A. Ferry, MD; Dennis W. Ross, MD, PhD; Annik van den Abbeele, MD; Claire Fung, MD; Nancy L. Harris, MD; Irene Kuter, MD; Peter Mauch, MD Page 2 Hodgkin Lymphoma • Hematologic System CAP Approved 2 © 2005. College of American Pathologists. ...

September, 2003 This Report on Leukemia, Lymphoma and Multiple Myeloma Contains: • Cancers by Age Group and Gender • Incidence Rates by Gender and Race • Survival Probabilities • Risk Factors • Sources of Additional Information The Ohio Cancer Incidence Surveillance System (OCISS) Blood-related cancers originate in the bone marrow (Leukemia and Multiple Myeloma) or lymphatic tissue (Non-Hodgkin’s and Hodgkin’s Lymphomas). These cancers involve the uncontrolled growth of cells with similar functions and origins and result from an acquired genetic injury to DNA of a single cell, which becomes malignant (cancerous) and multiplies continuously. The accumulation of malignant cells interferes with the body’s production of healthy blood cells and ability to protect itself against infections. ...

What we do o We provide timely access to evidence- based information on lymphoma and its treatments – independent of health industry funding . “Day or night, and without leaving home, patients can find answers in total privacy and without concern about asking a “dumb”question. We also provide site-specific search tools so that visitors have access to the latest information on lymphoma topics from the most credible sources . TOPIC SEARCH: ASCO | ASH | Cancer.gov ClinicalTrials.gov | Medscape | PubMed Guided by our scientific advisors and the published literature, we continuously update lymphomation.org as we respond to visitor questions and patient needs : We help patients to evaluate medical claims and data –and to recognize sources of bias and conflict of interest. o We provide the scientific community with ...

WINTER 2005 | 06 New Lymphoma Treatments are Saving Lives Story on page 2 96264A_d 12/7/05 9:06 AM Page 1 Page 2 RESEARCH 2 Treatment Advances for Lymphoma Have Reduced Deaths by 70% New state-of-the-art treatment advances for patients with follicular lymphoma , previously considered an incurable cancer, have reduced deaths in the first four years by 70 percent. A newly published study recommends that doctors carefully choose their patients’ initial ther- apies because there may be significant differences in overall survival rates, according to researchers at the James P. Wilmot Cancer Center. Scientists compared outcomes for 960 patients treated with three different regimens and survival rates vary from 91 percent for the newest treatments using monoclonal anti- bodies, to 69 ...

Copyright © 1998 by W.B. Saunders Company. All rights reserved. 300 A BASIC INFORMATION DESCRIPTION Malignant tumor of the lymphoid tissue (this is more common than Hodgkin’s disease). It involves the lym- phocytes (white blood cells), lymph glands (glands that fight infection and produce immune substances) and spleen (a large lymph gland). It can affect all ages, but is most common in men in their 40’s. FREQUENT SIGNS AND SYMPTOMS • Swollen, non-tender, rubbery, distinct lymph glands anywhere in the body but most commonly in the armpit, neck or groin. • Weight loss. • General ill feeling. • Anemia. • Bleeding from the gastrointestinal tract. • Jaundice (yellow skin and eyes). CAUSES Unknown, but research suggests a virus infection may be a factor or suppression of the immune system, par- ticularly after organ transplantation. One type ...

Summer, 2002 GWCCS Cancer Support Group & Internet Resource Guide Page 1 www.gwccs.org Greater Washington Coalition for Cancer Survivors (202) 364-6422 Leukemia Support Groups SPONSOR GROUP/ DESCRIPTION MEETING DAY/TIME LOCATION CONTACT & PHONE STATE Inova Fairfax Hospital --- Life With Cancer Leukemia Education Support Group 2nd Thursday 7:15 – 9:00 PM LWC Family Center 2832 Juniper St. Merrifield Marsha Komandt (703) 698-2841 VA John Hopkins University Hospital Patients – Leukemia, Lymphoma , Mult Myeloma 1st/3rd Monday 2:00-3:00 PM Oncology Center Lounge Alease Johnson (410) 955-6765 MD John Hopkins University Hospital Family – Leukemia, Lymphoma , Mult Myeloma 1 st Thursday 4:00-5:00 PM Oncology Center Lounge ...

1 Supplementary Information for DIFFUSE LARGE B-CELL LYMPHOMA OUTCOME PREDICTION BY GENE EXPRESSION PROFILING AND SUPERVISED MACHINE LEARNING Margaret A. Shipp, Ken N. Ross, Pablo Tamayo, Andrew P. Weng, Jeffery L. Kutok, Ricardo C. T. Aguiar, Michelle Gaasenbeek, Michael Angelo, Michael Reich, Geraldine S. Pinkus, Tane S. Ray, Margaret A. Koval, Kim W. Last, Andrew Norton, T. Andrew Lister, Jill Mesirov, Donna S. Neuberg, Eric S. Lander, Jon C. Aster, and Todd R. Golub December 6, 2001 Contents: Section I: Expanded Methods __ 3 Primary Lymphoma Specimens and Clinical Information _3 Microarray Hybridization_3 Preprocessing and Re-scaling _4 Supervised Learning4 Gene Marker Selection_5 Permutation Test and Neighborhood Analysis for Marker Genes _5 Algorithms__9 Weighted Voting 9 k-Nearest Neighbors (KNN) 9 Support Vector ...